arrow

From NeuroLex

Jump to: navigation, search



Resource:Laboratory of Molecular Neuroscience, University of Oslo

Name: Resource:Laboratory of Molecular Neuroscience, University of Oslo
Description: The Laboratory for Molecular Neuroscience investigates molecular mechanisms involved in the development of acute and chronic neurodegenerative disease, with a focus on the role of glutamate excitotoxicity. It aims at unraveling the molecular basis for cell death and edema development in stroke, and explores the pathophysiology of Alzheimer's disease and temporal lobe epilepsy. One of the long term goals is to identify new molecular targets for neuroprotective strategies in stroke and other conditions involving glutamate excitotoxicity.

The main objective of the LMN is to advance our understanding of the role of glutamate, as a transmitter substance in the normal brain and as a mediator of excitotoxicity in pathological conditions such as stroke. To this end the LMN employs several vital and non-vital imaging techniques. Model systems include organotypical slice cultures and transgene animals.

It is believed that the excitotoxic cascade ultimately leads to DNA damage, partly through excessive formation of oxygen radicals. Thus an important focus of the LMN is to explore the role of DNA damage and repair in the pathogenesis of neurodegenerative disease.

LMN is also engaged in research on molecular mechanism underlying brain edema, epilepsy, and Alzheimer's disease.

Clinical perspective of LMN's activities

The field of neurology continues to lag behind those of other disciplines when it comes to the range and efficacy of therapeutic strategies. In particular, common neurological conditions such as stroke, Alzheimer's disease, Parkinson's disease and other chronic neurodegenerative diseases, age-related cognitive impairment, epilepsy, mood disorders and schizophrenia call for new therapeutic strategies. Several of these conditions are particularly prevalent among the elderly and will constitute a growing health concern as the population ages. Most of the current molecular targets for neurological therapy are found in the monoamine and acetylcholine signaling systems, as use of receptor blockers or other drugs to interfere with the widespread fast signal transmission systems are causing substantial side effects. Future therapies will have to be based on strategies that act by reducing or increasing the number or activity of specific subtypes of pre- and postsynaptic receptors, transporters, and ion channels, or other membrane molecules at the synapse, and by strategies that exploit the new possibilities offered by stem cell technology and targeted repair.
Other Name(s): University of Oslo LMN
Abbreviation: UiO LMN
Parent Organization: University of Oslo; Oslo; Norway
Resource Type(s): Topical portal
Resource: Resource
URL: http://www.cmbn.no/ottersen/
*Id: nif-0000-11675
Keywords: epilepsy, excitotoxicity, acute, alzheimer's disease, brain, brain edema, cell death, chronic, damage, dna, glutamate, imaging, model systems, molecular, molecular mechanisms, neurodegenerative disease, neuroprotective, neuroscience, normal, repair, stroke, transmitter
Link to OWL / RDF: Download this content as OWL/RDF

Curation status: Curated

For Resource Owners:

A sitemap will keep your NIF Registry description up-to-date and inform search engines about your resource.

Please login to create the sitemap. (top right)

Learn more about what NIF can do for your resource.
Proudly proclaim your inclusion in NIF by displaying the "Registered with NIF" button on your site.

Notes

This page uses this default form:Resource

Contributors

Aarnaud, Ccdbuser, Eddy kim, Nifbot2



bookmark

*Note: Neurolex imports many terms and their ids from existing community ontologies, e.g., the Gene Ontology. Neurolex, however, is a dynamic site and any content beyond the identifier should not be presumed to reflect the content or views of the source ontology. Users should consult with the authoritative source for each ontology for current information.

Facts about Resource:Laboratory of Molecular Neuroscience, University of OsloRDF feed
AbbrevUiO LMN  +
CurationStatusuncurated  +
DefiningCitationhttp://www.cmbn.no/ottersen/  +
DefinitionThe Laboratory for Molecular Neuroscience The Laboratory for Molecular Neuroscience investigates molecular mechanisms involved in the development of acute and chronic neurodegenerative disease, with a focus on the role of glutamate excitotoxicity. It aims at unraveling the molecular basis for cell death and edema development in stroke, and explores the pathophysiology of Alzheimer's disease and temporal lobe epilepsy. One of the long term goals is to identify new molecular targets for neuroprotective strategies in stroke and other conditions involving glutamate excitotoxicity.

The main objective of the LMN is to advance our understanding of the role of glutamate, as a transmitter substance in the normal brain and as a mediator of excitotoxicity in pathological conditions such as stroke. To this end the LMN employs several vital and non-vital imaging techniques. Model systems include organotypical slice cultures and transgene animals.

It is believed that the excitotoxic cascade ultimately leads to DNA damage, partly through excessive formation of oxygen radicals. Thus an important focus of the LMN is to explore the role of DNA damage and repair in the pathogenesis of neurodegenerative disease.

LMN is also engaged in research on molecular mechanism underlying brain edema, epilepsy, and Alzheimer's disease.

Clinical perspective of LMN's activities

The field of neurology continues to lag behind those of other disciplines when it comes to the range and efficacy of therapeutic strategies. In particular, common neurological conditions such as stroke, Alzheimer's disease, Parkinson's disease and other chronic neurodegenerative diseases, age-related cognitive impairment, epilepsy, mood disorders and schizophrenia call for new therapeutic strategies. Several of these conditions are particularly prevalent among the elderly and will constitute a growing health concern as the population ages. Most of the current molecular targets for neurological therapy are found in the monoamine and acetylcholine signaling systems, as use of receptor blockers or other drugs to interfere with the widespread fast signal transmission systems are causing substantial side effects. Future therapies will have to be based on strategies that act by reducing or increasing the number or activity of specific subtypes of pre- and postsynaptic receptors, transporters, and ion channels, or other membrane molecules at the synapse, and by strategies that exploit the new possibilities offered by stem cell technology and targeted repair.
cell technology and targeted repair.
Has default formThis property is a special property in this wiki.Resource  +
Has roleTopical portal  +
Idnif-0000-11675  +
Is part ofUniversity of Oslo; Oslo; Norway  +
KeywordsEpilepsy  +, Excitotoxicity  +, Acute  +, Alzheimer's disease  +, Brain  +, Brain edema  +, Cell death  +, Chronic  +, Damage  +, Dna  +, Glutamate  +, Imaging  +, Model systems  +, Molecular  +, Molecular mechanisms  +, Neurodegenerative disease  +, Neuroprotective  +, Neuroscience  +, Normal  +, Repair  +, Stroke  +, and Transmitter  +
LabelResource:Laboratory of Molecular Neuroscience, University of Oslo  +
ModifiedDate10 May 2012  +
Page has default formThis property is a special property in this wiki.Resource  +
SuperCategoryResource  +
SynonymUniversity of Oslo LMN  +